Compare RVMD & EL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | EL |
|---|---|---|
| Founded | 2014 | 1946 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 30.3B |
| IPO Year | N/A | 2007 |
| Metric | RVMD | EL |
|---|---|---|
| Price | $189.23 | $84.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $140.84 | $97.60 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 1.85% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $14,326,000,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | $533.02 | $4.08 |
| P/E Ratio | ★ N/A | $103.61 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.00 | $66.22 |
| 52 Week High | $194.56 | $121.64 |
| Indicator | RVMD | EL |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 54.02 |
| Support Level | $176.00 | $80.06 |
| Resistance Level | $193.83 | $87.57 |
| Average True Range (ATR) | 7.45 | 2.25 |
| MACD | -0.96 | 0.37 |
| Stochastic Oscillator | 58.24 | 75.61 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%). Top-selling brands include Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.